This project aims at utilizing camelide antibodies, which are much smaller then human antibodies, to, together with surface specialists at the Austrian Institute of Technologies (AIT), create a surface with high density of immobilized Camelid antibodies and therefore better binding affinity of target molecules or molecule groups.
Those surfaces are meant to be applied in products for therapeutic apheresis, together with Fresenius Medical Care, to achieve improved purification of and removal of specific harmful substances from patient blood.